AZN

Peers: LLY MRK PFE ABBV JNJ NVS GSK BMY SNY AMGN

| Held by: PVAL AVDE DIHP DFIC PBPH PPH FVD DFAX BDYN IDEQ

Index	-
Market Cap	245.61B
Enterprise Value	272.95B
Income	10.45B
Sales	61.37B
Book/sh	32.43
Cash/sh	3.20
Dividend Est.	3.34 (2.11%)
Dividend TTM	3.23 (2.04%)
Dividend Ex-Date	Aug 07, 2026
Dividend Gr. 3/5Y	1.78% 3.25%
Payout	47.19%
Employees	96100
IPO	Oct 17, 2003

P/E	23.67
Forward P/E	13.81
PEG	1.19
P/S	4.00
P/B	4.88
P/C	49.44
P/FCF	22.60
EV/EBITDA	13.59
EV/Sales	4.45
Quick Ratio	0.67
Current Ratio	0.89
Debt/Eq	0.64
LT Debt/Eq	0.52
Option/Short	Yes / Yes

EPS (ttm)	6.69
EPS next Y	11.46
EPS next Q	2.60
EPS this Y	12.06%
EPS next Y	11.69%
EPS next 5Y	11.65%
EPS past 3/5Y	45.90% 22.05%
Sales past 3/5Y	9.82% 16.31%
EPS Y/Y TTM	25.90%
Sales Y/Y TTM	8.61%
EPS Q/Q	2.26%
Sales Q/Q	6.41%
Earnings	Jul 27 BMO
EPS/Sales Surpr.	5.98% -0.32%

Insider Own	3.44%
Insider Trans	-0.02%
Inst Own	60.86%
Inst Trans	-1.02%
ROA	9.15%
ROE	21.99%
ROIC	13.69%
Gross Margin	73.93%
Oper. Margin	22.38%
Profit Margin	17.02%
SMA20	-2.60%
SMA50	-2.44%
SMA200	-12.71%
Trades

Shs Outstand	1.55B
Shs Float	1.50B
Short Float	0.14%
Short Ratio	0.61
Short Interest	2.09M
52W High	212.71 -25.55%
52W Low	153.41 3.23%
Volatility	1.92% 1.77%
ATR (14)	3.24
RSI (14)	42.48
Beta	0.32
Rel Volume	0.61
Avg Volume	3.40M
Volume	1,555,143

Perf Week	0.42%
Perf Month	0.91%
Perf Quarter	-7.72%
Perf Half Y	-22.75%
Perf YTD	-9.76%
Perf Year	-7.98%
Perf 3Y	18.64%
Perf 5Y	27.89%
Perf 10Y	148.57%
Recom	1.60
Target Price	219.33
Prev Close	160.12
Price	158.37
Change %	-1.10%

Date	Action	Analyst	Rating Change
Sep-15-26	Upgrade	Deutsche Bank	Sell → Hold
Sep-09-26	Initiated	RBC Capital Mkts	Outperform
Jul-13-26	Downgrade	HSBC Securities	Buy → Hold

Today 09:00AM	SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology (PR Newswire)
09:00AM	Pharmas $500B patent problem will come in waves not as a cliff (Pharma Voice)
Oct-07-26 09:09AM	Micro-Cap Stock Veraxa Biotech Is Down 96% This Year. Can Next-Gen Drug Testing Save It? (Barrons.com)
07:00AM	Jefferies maintains 'buy' rating on AstraZeneca ahead of third-quarter results (Proactive)
Oct-06-26 10:01PM	Goldman Sachs Says China Biotech Is Where Big Pharma Is Shopping Now (BeInCrypto)
09:00AM	Loading…
09:00AM	Citi raises AstraZeneca target to £186 as tozorakimab prospects improve (Proactive)
07:44AM	AstraZeneca CEO Pascal Soriot on Summit ivonescimab combos (Quartz)
06:41AM	AstraZeneca opens new R&D centre in Cambridge, US (Pharmaceutical Business Review)
Oct-05-26 04:30PM	AstraZeneca CEO says Summit drug could drive next generation of cancer combinations (CNBC TV)
01:52PM	AstraZeneca opens $1 billion R&D center in Massachusetts (Quartz)
12:01PM	AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts (Business Wire)
09:36AM	Will there be more to Daiichis story than DXd ADCs? (Pharma Voice)
07:00AM	AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics (Business Wire)
Oct-02-26 08:13PM	Stocktwits Biotech Dealmaker Novartis, Sanofi And Novo Sign Weeks Biggest Deals (Stocktwits)
01:58PM	AstraZeneca Stocks Moves Lower as Datroway Combination Enters Phase 3 (GuruFocus.com)
10:30AM	Loading…
10:30AM	AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact (Pharmaceutical Technology)
08:38AM	Summit Teams Up With Daiichi Sankyo, AstraZeneca For Cancer Therapy Trial CEO Calls It An Important Expansion (Stocktwits)
Oct-01-26 07:57PM	AstraZeneca Stocks Drops as $2 Billion Buys an Oncology Option (GuruFocus.com)
Sep-30-26 10:32AM	Adding Lilly's new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects. (MarketWatch)
Sep-29-26 01:17PM	AstraZeneca Stock Slips as $2 Billion Summit Stake Deepens Oncology (GuruFocus.com)
12:07PM	Summit Stock Jumps 17% on $2 Billion AstraZeneca Investment (GuruFocus.com)
08:49AM	AstraZeneca invests $2B in Summit, gaining seat at the table for PD-1/VEGF drug push (BioPharma Dive)
08:30AM	AstraZenecas $2 billion Summit stake wins backing from UBS and Jefferies (Proactive)
07:39AM	Premarket movers: FICO sinks while Summit, AAR and CarMax rise (Investing.com)
06:34AM	AstraZeneca to invest $2bn in Summit for ADC combination therapies (Pharmaceutical Technology)
06:24AM	Summit Therapeutics Shares Rise 22% After $2 Billion AstraZeneca Investment (InvestorsHub)
02:32AM	AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal (Proactive)
Sep-28-26 07:35PM	SMMT Stock Soars After-Hours: Did AstraZeneca Just End Summits Cash Scare? (Stocktwits)
06:08PM	Summit shares surge after-hours on $2 billion AstraZeneca equity deal (Investing.com)
05:30PM	AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics (Business Wire)
08:50AM	Loading…
08:50AM	What Bavarian Nordics next CEO is up against (Pharma Voice)
Sep-25-26 08:00AM	Nuvectis' In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It's Not Even Their Lead Asset (FinanceWire)
Sep-23-26 10:52AM	European big pharma unites amid ringing alarm bells of continents dominance (Clinical Trials Arena)
08:41AM	Novo Nordisk Stock Slides After Unveiling Long Term Pipeline Growth Targets (TIKR)
05:55AM	Biotech is one area where the US can afford to let China flourish (Financial Times)
12:00AM	Ozempic-maker Novo open to upgrading US listing (Financial Times)
Sep-22-26 03:26PM	AstraZeneca and GSK warn Europes drug industry is at risk (The Telegraph)
Sep-21-26 11:55AM	Novo Nordisk shares plunge over 7% as new targets fail to reassure investors (Proactive)
08:20AM	Novo Nordisk Stock Drops 5.6% as 2030 Goals Match Peers (GuruFocus.com)
Sep-17-26 03:16PM	AstraZeneca Gains as Enhertu Clears England's Value Gate (GuruFocus.com)
01:00AM	The West is hooked on Chinese drugs but they could save your life (The Telegraph)
Sep-16-26 03:03PM	AstraZeneca Shares Rise as J.P. Morgan Stays Overweight (GuruFocus.com)
10:37AM	AstraZeneca shares oversold after trial flops and merger talk, says UBS (Proactive)
07:05AM	AstraZeneca's news flow next year could sustain drugs group beyond 2030, says leading bank (Proactive)
Sep-15-26 08:02AM	WCLC 26: A new ADC era, China questions and AstraZenecas spotlight (BioPharma Dive)
07:11AM	CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot (Stocktwits)
Sep-14-26 12:46PM	AstraZenecas cancer pipeline posts two wins and a loss (Clinical Trials Arena)
08:30AM	AstraZenecas newly approved pill fails frontline breast cancer study (BioPharma Dive)
08:10AM	Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results (InvestorsHub)
08:01AM	AstraZeneca breast cancer drug fails trial but Citi keeps 'buy' rating (Proactive)
Sep-11-26 06:11PM	AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss Executive Disappointed, Reiterates Breast Cancer Focus (Stocktwits)
Sep-10-26 08:30AM	AstraZeneca's $5bn drug promise is no 'buy' signal for Deutsche (Proactive)
Sep-09-26 02:02PM	AstraZeneca Falls 1.3% Despite a 34% COPD Breakthrough (GuruFocus.com)
02:01PM	Amgen's Imdelltra Sales Surge 115% as Lung-Cancer Combination Meets Major Goals (GuruFocus.com)
11:56AM	ERS 2026: tozorakimabs groundbreaking exacerbation reduction sets a new bar in COPD (Clinical Trials Arena)
11:46AM	VERAXA Biotech Designates Raju Willener as CFO (Exec Edge)
09:00AM	AstraZeneca COPD data back Citi's $7b peak sales case (Proactive)
06:10AM	Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study (InvestorsHub)
05:48AM	Merck pairs ADCs with Keytruda in womens cancer push (Pharma Voice)
Sep-08-26 12:35PM	AstraZeneca Falls Today Even as Imfinzi Wins a Landmark Survival Test (GuruFocus.com)
10:41AM	Roivant surges on exceptional results; Bristol Myers touts first-of-its-kind CAR-T therapy (BioPharma Dive)
08:28AM	AstraZeneca tozorakimab COPD Phase 3 trial results 2026 (Quartz)
Sep-07-26 10:03AM	Citi backs AstraZeneca sentiment boost after Etcamah wins accelerated FDA approval (Proactive)
07:14AM	Evinova and Lothar Medical partner on respiratory device trials (Medical Device Network)
05:35AM	FDA approves AstraZeneca's Etcamah combo for advanced breast cancer (Pharmaceutical Business Review)
Sep-04-26 07:56AM	This week in charts: China deals, stock flatlines and Lillys M&A spree (BioPharma Dive)
Sep-03-26 08:00AM	Some of the Top Biotech Funds Just Bought Into This Under-the-Radar Biotech (NASDAQ: NVCT) (FinanceWire)
Sep-02-26 04:36PM	Top Stock Reports for AMD, Costco & AstraZeneca (Zacks)
Sep-01-26 01:19PM	AstraZeneca's $80 Billion Plan Gets Another Tagrisso Win (GuruFocus.com)
Aug-30-26 10:29PM	SLS Stock Rises Overnight: Healthcare Execs Tout AML Drug As Game Changer Ahead Of Final Trial Trigger (Stocktwits)
Aug-28-26 05:18PM	IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial Jefferies Sees Neutral To Negative Readthrough To ALNY (Stocktwits)
08:54AM	Alnylam stock drops on rival heart trial: Why analysts see core business safe (Investing.com)
06:58AM	AstraZeneca, Ionis data spark debate about RNA drugs impact on deadly heart disease (BioPharma Dive)
Aug-27-26 03:10PM	AstraZeneca Stock Remains 14% Lower Despite Tezspire Phase 3 Success (GuruFocus.com)
07:58AM	New data could widen use of AstraZeneca, Amgen immune disease drug (BioPharma Dive)
07:30AM	Amgen-AstraZenecas Tezspire nets another Phase III inflammatory disease win (Clinical Trials Arena)
03:18AM	AstraZeneca drug succeeds in trial for swallowing disorder (Proactive)
Aug-26-26 01:51PM	Summits Global Lung Cancer Trials Gain Credibility After Akesos Phase 3 Data, Says Guggenheim (Stocktwits)
07:29AM	Akeso logs Phase III success in second tumour type for ivonescimab (Clinical Trials Arena)
Aug-25-26 02:32AM	AstraZeneca prices 2.55bn euro bond sale across four tranches (Proactive)
Aug-20-26 12:29PM	Big Pharma is Making Chinese Biotechs Prosper (Moby)
Aug-19-26 06:30AM	HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation (TMX Newsfile)
05:30AM	The Key to Pharma M&A: Never Shopping Hungry (The Wall Street Journal)
Aug-18-26 09:00AM	AstraZeneca maintains Citi 'buy' rating despite mixed pipeline updates (Proactive)
07:13AM	AstraZeneca scores in lung cancer; Sandoz inks a China deal (BioPharma Dive)
Aug-17-26 04:42PM	AstraZeneca Halts Key Lung-Cancer Trial--But Shares Barely Flinch (GuruFocus.com)
10:37AM	HUTCHMED shares rise as lung cancer drug trial hits key targets (Proactive)
10:07AM	AstraZenecas Lung Cancer Bet Hits a Dead End (Moby)
02:41AM	AstraZeneca lung cancer drug combination extends survival in trial (Proactive)
02:41AM	AstraZeneca halts lung cancer trial in fresh pipeline setback (Proactive)
Aug-13-26 04:00PM	Sarah Ketterer's Top Q2 2026 Move: AstraZeneca PLC at a 3.92% Portfolio Impact (GuruFocus.com)
Aug-12-26 12:00AM	How AstraZenecas $400bn deal unravelled (Financial Times)
Aug-07-26 03:30PM	Roche Stock Jumps as Morgan Stanley Sees Drug Breakout (GuruFocus.com)
06:02AM	Significant demand for Revolution drug; Intellia pinpoints liver toxicity culprit (BioPharma Dive)
01:00AM	Why FTSE companies are heading for the exit (The Telegraph)
01:00AM	The 20-year exodus hollowing out the London stock market (The Telegraph)
01:00AM	How the FTSE became a departure lounge for British companies (The Telegraph)
12:01AM	For Modernas Greenlit mRNA Flu Vaccine, Payoff Is a Ways Off (The Daily Upside)
Aug-06-26 05:26AM	What the AstraZeneca-BMS rumors reveal about pharma megamergers (Pharma Voice)
Aug-05-26 12:17PM	AstraZeneca-Bristol Myers $400B Merger Buzz Cools After Report Denies Talks There Never Was A Deal To Be Done (Stocktwits)

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

M.B.A.Mr. Pascal Claude Roland Soriot D.V.M.

CFO & Executive DirectorDr. Aradhana Sarin M.D.

EVP of Global opt. & ITMs. Pam P. Cheng

Head of Investor RelationsMr. Joris Silon

CHROMr. Jeffrey Pott J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sharma Mani	See Remarks	Aug 08 '26	Buy	160.57	20	3,249	19,288	Sep 11 04:05 PM
Sharma Mani	See Remarks	May 20 '26	Sale	185.78	11,893	2,209,482	19,262	May 22 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Astrazeneca plc

Upgrade your Finviz experience